Phase 2 Study of Dacomitinib in NSCLC

Conditions:   NSCLC Stage IIIB;   NSCLC Stage IV;   Recurrent NSCLC;   EGFR Positive Non-Small Cell Lung Cancer Intervention:   Drug: Dacomitinib Sponsors:   National Cancer Centre, Singapore;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials